Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

National Institute of Allergy and Infectious Diseases (NIAID)44 enrolled

Overview

The purpose of this study is to determine the safety and effectiveness of the anti-HIV drugs efavirenz and lamivudine/zidovudine given to treatment-naive HIV-infected people in Dakar, Senegal.

Despite a relatively low prevalence of HIV infection, all HIV subtypes have been documented in Senegal. Data on mutations that confer resistance to antiretroviral (ARV) drugs are limited to HIV subtype B; adherence data are also limited. The study will evaluate the safety and efficacy of an ARV regimen given to treatment-naive HIV infected adults and adolescents. The study will also examine the characteristics of virologic failure and adherence in this treatment group. Participants will be recruited at two sites in Dakar, Senegal. This study will last 96 weeks. At study entry, all participants will be given an ARV regimen of lamivudine/zidovudine twice daily and efavirenz once daily. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens. There will be 14 study visits during the study; a physical exam, blood collection, and sociodemographic and medication history assessments will occur at each visit. Participants will also be asked to complete quality-of-life and adherence questionnaires. An off-study visit will occur at approximately one month after Week 96, with assessments and procedures similar to visits during the study.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

HIV Infections

Interventions

EfavirenzDRUG

600 mg tablet taken orally daily

Lamivudine/zidovudineDRUG

150mg lamivudine/300mg zidovudine tablet taken orally twice daily

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV-infected * Have never taken ARV drugs * CD4 count of 200 cells/mm3 or less within 30 days of study entry if asymptomatic OR CD4 count of 350 cells/mm3 or less within 60 days of study entry if CDC Category A or B clinical condition present OR clinical diagnosis of AIDS, regardless of CD4 count * Willing to stay in the study area for the duration of the study * Willing to use acceptable forms of contraception Exclusion Criteria: * HIV-2 infected * Systemic chemotherapy (except interferon) within 6 months prior to study entry * Current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study * Serious illness, including any active AIDS-defining infection, active tuberculosis, malaria, or any illness requiring systemic treatment or hospitalization. People who have completed therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded. * Serious psychiatric problems within 60 days of study entry, including depression, suicidal thoughts or attempts, aggressive behavior, or psychosis-like symptoms * Have taken certain medications within 30 days of study entry * Pregnancy or breastfeeding

Locations (2)

Centre National Hospitalier de Fann, Dakar CIPRA CRS

Dakar, Senegal

Institut d'Hygiène Sociale, Dakar CIPRA CRS

Dakar, Senegal

Outcomes

Primary Outcomes

Virologic efficacy, defined as HIV-1 viral load less than 200 copies/ml

Time frame: Through Week 24

Treatment-related toxicity of Grade 3 or higher as measured by development of drug-related toxicities severe enough to warrant dose modification, interruption, or permanent discontinuation

Time frame: Through Week 24

Secondary Outcomes

Virologic efficacy

Time frame: At Weeks 48 and 96

Treatment related toxicity

Time frame: At Weeks 48 and 96

Virologic failure, defined as HIV-1 viral load greater than 1,000 copies/ml

Time frame: Throughout study

CD4 counts and HIV-1 RNA viral load

Time frame: Throughout study

First new or recurrent AIDS-defining event (as defined by the CDC Expanded AIDS Surveillance Case definition) or death

Time frame: Throughout study

Treatment discontinuation, defined as premature discontinuation of participation in the study, failure to take ARV therapy for 8 or more consecutive weeks, or to switch to another ARV regimen for any reason during the full course of the study

Time frame: Throughout study

Genotypic resistance measured by at least 1 genotypic mutation associated with resistance among subjects with a confirmed virologic failure (as described previously) and evaluation of genotypic drug resistance patterns

Time frame: At Weeks 24 and 96

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.